Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companies Clearing Cell And Gene Therapy Manufacturing Hurdles

This article was originally published in Scrip

Executive Summary

The promise of cell and gene therapies is great, but there's a lot of work to be done between selecting a clinical candidate and eventually selling an approved product, and companies have learned that commercial scale manufacturing is a challenge that has to be addressed early on in development.

Advertisement

Related Content

Much Anticipated JULIET Data Show Novartis Playing Catch-Up On CAR-T Manufacturing
Juno, Kite Stand By Their Products As Novartis's Shift Renews CAR-T Concerns

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC030011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel